CTS Corporation’s first quarter results fell short of Wall Street’s expectations, with both revenue and adjusted earnings per share missing analyst estimates. The market responded negatively, reflecting investor concern about flat sales and margin pressures. Management attributed the quarter’s performance to strong momentum in its diversified end markets—particularly medical, industrial, and aerospace and defense—while softness in the transportation segment, especially due to weaker commercial vehicle demand and challenging China market dynamics, offset these gains. CEO Kieran O’Sullivan highlighted a 14% increase in diversified market revenue and emphasized ongoing progress with new product wins and customer additions, particularly in medical therapeutics and aerospace applications.
Is now the time to buy CTS? Find out in our full research report (it’s free).
CTS (CTS) Q1 CY2025 Highlights:
- Revenue: $125.8 million vs analyst estimates of $128.7 million (flat year on year, 2.3% miss)
- Adjusted EPS: $0.44 vs analyst expectations of $0.49 (10.2% miss)
- Adjusted EBITDA: $25.8 million vs analyst estimates of $27.05 million (20.5% margin, 4.6% miss)
- The company reconfirmed its revenue guidance for the full year of $535 million at the midpoint
- Management reiterated its full-year Adjusted EPS guidance of $2.28 at the midpoint
- Operating Margin: 13.3%, in line with the same quarter last year
- Market Capitalization: $1.29 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions CTS’s Q1 Earnings Call
- John Franzreb (Sidoti): Asked whether elevated bookings in diversified markets were due to customers preordering ahead of tariff changes; CEO Kieran O’Sullivan clarified that medical bookings were for longer-term needs, with limited evidence of broad prebuying.
- John Franzreb (Sidoti): Questioned transportation market assumptions post-tariff; O’Sullivan noted some prebuying but said guidance assumes steady conditions and highlighted a new transportation product win.
- Hendi Susanto (Gabelli Funds): Inquired about manufacturing footprint and tariff mitigation; O’Sullivan explained regional manufacturing strategies and highlighted the importance of USMCA (U.S.-Mexico-Canada Agreement) exemptions, with ongoing evaluation of logistics and pricing adjustments.
- John Franzreb (Sidoti): Asked about the sustainability of higher SG&A expenses; CFO Ashish Agrawal cited SyQwest integration as the main driver and stated that discretionary spending will be carefully managed as tariff risks evolve.
- Hendi Susanto (Gabelli Funds): Requested clarity on drivers of margin improvement; Agrawal confirmed that growth in diversified markets and operational efficiencies would be key contributors, with ongoing vigilance on tariffs and currency impacts.
Catalysts in Upcoming Quarters
Looking forward, the StockStory team will be monitoring (1) the pace of revenue growth and profitability in the diversified medical, industrial, and aerospace segments, (2) the effectiveness of SyQwest integration and realization of government contract revenue, and (3) how well CTS navigates ongoing tariff and geopolitical uncertainties, particularly in the transportation business. Key product launches and new customer wins will also be important markers of progress.
CTS currently trades at $43.30, up from $39.89 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
